<?xml version='1.0' encoding='utf-8'?>
<document id="27159430"><sentence text="Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration."><entity charOffset="20-33" id="DDI-PubMed.27159430.s1.e0" text="acenocoumarol" /><entity charOffset="35-45" id="DDI-PubMed.27159430.s1.e1" text="ombitasvir" /><entity charOffset="46-58" id="DDI-PubMed.27159430.s1.e2" text="paritaprevir" /><entity charOffset="59-68" id="DDI-PubMed.27159430.s1.e3" text="ritonavir" /><entity charOffset="73-82" id="DDI-PubMed.27159430.s1.e4" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e0" e2="DDI-PubMed.27159430.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e0" e2="DDI-PubMed.27159430.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e0" e2="DDI-PubMed.27159430.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e0" e2="DDI-PubMed.27159430.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e0" e2="DDI-PubMed.27159430.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e1" e2="DDI-PubMed.27159430.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e1" e2="DDI-PubMed.27159430.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e1" e2="DDI-PubMed.27159430.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e1" e2="DDI-PubMed.27159430.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e2" e2="DDI-PubMed.27159430.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e2" e2="DDI-PubMed.27159430.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e2" e2="DDI-PubMed.27159430.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e3" e2="DDI-PubMed.27159430.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s1.e3" e2="DDI-PubMed.27159430.s1.e4" /></sentence><sentence text="Limited data are available on co-administration of acenocoumarol with direct-acting antiviral agents for chronic hepatitis C virus infection"><entity charOffset="51-64" id="DDI-PubMed.27159430.s2.e0" text="acenocoumarol" /></sentence><sentence text="" /><sentence text="We report a case of a patient who required a significant increase in acenocoumarol weekly dose probably due to an interaction with ombitasvir/paritaprevir/ritonavir and/or dasabuvir"><entity charOffset="69-82" id="DDI-PubMed.27159430.s4.e0" text="acenocoumarol" /><entity charOffset="131-141" id="DDI-PubMed.27159430.s4.e1" text="ombitasvir" /><entity charOffset="142-154" id="DDI-PubMed.27159430.s4.e2" text="paritaprevir" /><entity charOffset="155-164" id="DDI-PubMed.27159430.s4.e3" text="ritonavir" /><entity charOffset="172-181" id="DDI-PubMed.27159430.s4.e4" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e0" e2="DDI-PubMed.27159430.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e0" e2="DDI-PubMed.27159430.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e0" e2="DDI-PubMed.27159430.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e0" e2="DDI-PubMed.27159430.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e0" e2="DDI-PubMed.27159430.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e1" e2="DDI-PubMed.27159430.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e1" e2="DDI-PubMed.27159430.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e1" e2="DDI-PubMed.27159430.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e1" e2="DDI-PubMed.27159430.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e2" e2="DDI-PubMed.27159430.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e2" e2="DDI-PubMed.27159430.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e2" e2="DDI-PubMed.27159430.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e3" e2="DDI-PubMed.27159430.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s4.e3" e2="DDI-PubMed.27159430.s4.e4" /></sentence><sentence text=" A causality assessment of the drug-drug interaction leading to a reduced INR was conducted according to the Naranjo algorithm" /><sentence text=" A score of 6 suggested that the adverse drug reaction was probable" /><sentence text="" /><sentence text="Because of possible INR abnormalities during the concomitant use of acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir, clinicians should closely monitor INR values"><entity charOffset="68-81" id="DDI-PubMed.27159430.s8.e0" text="acenocoumarol" /><entity charOffset="83-93" id="DDI-PubMed.27159430.s8.e1" text="ombitasvir" /><entity charOffset="94-106" id="DDI-PubMed.27159430.s8.e2" text="paritaprevir" /><entity charOffset="107-116" id="DDI-PubMed.27159430.s8.e3" text="ritonavir" /><entity charOffset="121-130" id="DDI-PubMed.27159430.s8.e4" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e0" e2="DDI-PubMed.27159430.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e0" e2="DDI-PubMed.27159430.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e0" e2="DDI-PubMed.27159430.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e0" e2="DDI-PubMed.27159430.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e0" e2="DDI-PubMed.27159430.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e1" e2="DDI-PubMed.27159430.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e1" e2="DDI-PubMed.27159430.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e1" e2="DDI-PubMed.27159430.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e1" e2="DDI-PubMed.27159430.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e2" e2="DDI-PubMed.27159430.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e2" e2="DDI-PubMed.27159430.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e2" e2="DDI-PubMed.27159430.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e3" e2="DDI-PubMed.27159430.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27159430.s8.e3" e2="DDI-PubMed.27159430.s8.e4" /></sentence><sentence text="" /></document>